Why the study?
Are patients with acute coronary syndrome and comorbid diabetes mellitus or chronic kidney disease less likely to receive prasugrel or ticagrelor compared to clopidogrel?
Cohort (n=98,649)
Are patients with acute coronary syndrome and comorbid diabetes mellitus or chronic kidney disease less likely to receive prasugrel or ticagrelor compared to clopidogrel?
Answers are grounded in this paper and cite their sources.
Despite being at higher risk for recurrent events, ACS patients with comorbid CKD and/or diabetes are less likely to receive more potent third-generation P2Y12 inhibitors compared to clopidogrel.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Desai et al. (2017) conducted a cohort in Acute coronary syndrome (n=98,649). Chronic kidney disease vs. No chronic kidney disease was evaluated on Initiation of prasugrel versus clopidogrel (OR 0.81, 95% CI 0.74-0.88).
Synapse has enriched 10 related papers. Consider them for comparative context: